Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 21, 2015

View Archived Issues

Genethon licenses CEVEC's lentivirus packaging cell line technology

Topica Pharmaceuticals to advance 10% luliconazole program into phase III development

Nestle Health Science licenses rights to Lipid Therapeutics' LT-02

Alector raises funds to advance immunomodulation approach for neurodegenerative diseases

Topline results from Apricus' phase IIa trial of RayVa for Reynaud's phenomenon

Arch Biopartners completes preclinical validation studies for AB-569

Infinity Pharmaceuticals adds IPI-549 to its pipeline for the treatment of solid tumors

FDA grants QIDP designation to Cempra's fusidic acid antibiotic

Shire's Intuniv approved in E.U. for ADHD

Novel MAb treats diabetes and fatty liver disease in obesity models

FDA accepts for review Heron's NDA resubmission for Sustol

FDA awards fast track designation to ZMapp for Ebola virus disease

Soluble Nogo-B improves angiogenesis in vitro

Cadila discloses BTK inhibitors

Takeda patents TBK1 inhibitors

Bristol-Myers Squibb presents MGAT2 inhibitors

Chinese researchers report discovery of compounds for psychiatric/neurological disorders

McGill University patent describes TC-PTP inhibitors

Pluristem and FDA agree development pathway for PLX-R18 in ARS

Beta-lactamase inhibitor CB-618 pharmacokinetics-pharmacodynamics characterized with other agents

Swissmedic approves Novartis's Entresto for heart failure

Clinigen and Neuraltus partner on managed access program for NP-001 in Europe

First clinical results disclosed for Enanta's EDP-239

New biomarkers described for liver transplant

Genmab and Novartis granted priority review for ofatumumab sBLA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...